Servicio de Cardiología, Hospital General Universitario Gregorio Marañón y Universidad Europea de Madrid, Madrid, Spain.
J Intern Med. 2014 Jun;275(6):608-20. doi: 10.1111/joim.12174. Epub 2014 Mar 27.
To study the factors associated with choice of therapy and prognosis in octogenarians with severe symptomatic aortic stenosis (AS).
Prospective, observational, multicenter registry. Centralized follow-up included survival status and, if possible, mode of death and Katz index.
Transnational registry in Spain.
We included 928 patients aged ≥80 years with severe symptomatic AS.
Aortic-valve replacement (AVR), transcatheter aortic-valve implantation (TAVI) or conservative therapy.
All-cause death.
Mean age was 84.2 ± 3.5 years, and only 49.0% were independent (Katz index A). The most frequent planned management was conservative therapy in 423 (46%) patients, followed by TAVI in 261 (28%) and AVR in 244 (26%). The main reason against recommending AVR in 684 patients was high surgical risk [322 (47.1%)], other medical motives [193 (28.2%)], patient refusal [134 (19.6%)] and family refusal in the case of incompetent patients [35 (5.1%)]. The mean time from treatment decision to AVR was 4.8 ± 4.6 months and to TAVI 2.1 ± 3.2 months, P < 0.001. During follow-up (11.2-38.9 months), 357 patients (38.5%) died. Survival rates at 6, 12, 18 and 24 months were 81.8%, 72.6%, 64.1% and 57.3%, respectively. Planned intervention, adjusted for multiple propensity score, was associated with lower mortality when compared with planned conservative treatment: TAVI Hazard ratio (HR) 0.68 (95% confidence interval [CI] 0.49-0.93; P = 0.016) and AVR HR 0.56 (95% CI 0.39-0.8; P = 0.002).
Octogenarians with symptomatic severe AS are frequently managed conservatively. Planned conservative management is associated with a poor prognosis.
研究 80 岁以上严重症状性主动脉瓣狭窄(AS)患者治疗选择和预后的相关因素。
前瞻性、观察性、多中心注册研究。集中随访包括生存状况,如有可能,还包括死亡方式和 Katz 指数。
西班牙跨国注册中心。
我们纳入了 928 名 80 岁以上的严重症状性 AS 患者。
主动脉瓣置换术(AVR)、经导管主动脉瓣植入术(TAVI)或保守治疗。
全因死亡。
平均年龄为 84.2±3.5 岁,仅有 49.0%的患者为独立(Katz 指数 A)。最常见的计划治疗是 423 例(46%)患者的保守治疗,其次是 261 例(28%)的 TAVI 和 244 例(26%)的 AVR。在 684 例患者中,不建议进行 AVR 的主要原因是手术风险高[322 例(47.1%)]、其他医学原因[193 例(28.2%)]、患者拒绝[134 例(19.6%)]和无法手术的患者家属拒绝[35 例(5.1%)]。从治疗决策到 AVR 的平均时间为 4.8±4.6 个月,到 TAVI 的平均时间为 2.1±3.2 个月,P<0.001。在随访期间(11.2-38.9 个月),357 例患者(38.5%)死亡。6、12、18 和 24 个月的生存率分别为 81.8%、72.6%、64.1%和 57.3%。与计划保守治疗相比,调整多个倾向评分后的计划干预与死亡率降低相关:TAVI 风险比(HR)0.68(95%置信区间[CI] 0.49-0.93;P=0.016)和 AVR HR 0.56(95% CI 0.39-0.8;P=0.002)。
有症状的严重 AS 老年患者常接受保守治疗。计划保守治疗与预后不良相关。